Objective:

To report experience in a hospital in Mexico regarding oncological results in overall survival (OS) and specific cancer survival (SCS), the presence of recurrence in the management of residual masses after chemotherapy with lymphadenectomy retroperitoneal for 15 years.

Method:

Between 2004 and 2019, a retrospective study was carried out in a single centre with patients with a germ cell tumor diagnosis who have received first or second line of chemotherapy and who present retroperitoneal residual mass were included have performed RPLND. Sociodemographic characteristics were analyzed, overall and histological survival.

Results:

346 patients had inclusion criteria, mean age was 27.6 years, the most affected testis was the left, the most frequent testicular histology was mixed germline. The most frequent retroperitoneal location was paraortic, the most frequent type of RPLND was standard, the most frequent histology was necrosis. Recurrence occurred in 24.2%, mean of 17.1 months, when analyzing individual factors, the most significant was the type of RPLND. The clinical stage, histology of the retroperitoneal tumor and type of RPLND influence mortality. Global follow up of 141 months, OS was 85.5% and SCS was 86.1%, mean of 139.9 months and 141 months respectively.

Conclusions:

RPLND is effective in survival and recurrence in advanced disease in patients who present postchemotherapy retroperitoneal tumor and although there is a clear benefit in the resection of retroperitoneal tumors in teratoma, there are conditioning factors that must be analyzed individually.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )